Statistical analysis plan for stage 1 EMBARC (Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care) study

Contemporary Clinical Trials Communications

Volumn 6, Issue , 2017, Pages 22-30

  Petkova, Eva ^a,b   Ogden, R Todd ^c   Tarpey, Thaddeus ^a,d   Ciarleglio, Adam ^a,c   Jiang, Bei ^e   Su, Zhe ^a   Carmody, Thomas ^f   Adams, Philip ^g,h   Kraemer, Helena C ⁱ   Grannemann, Bruce D ^f   Oquendo, Maria A ^g,h   Parsey, Ramin ^j   Weissman, Myrna ^g,h   McGrath, Patrick J ^g,h   Fava, Maurizio ^k   Trivedi, Madhukar H ^f  

^a NEW YORK UNIVERSITY   (United States)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d WRIGHT STATE UNIVERSITY   (United States)

^e UNIVERSITY OF ALBERTA   (Canada)

^f UNIVERSITY OF TEXAS AT DALLAS   (United States)

^g NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^h College of Physicians and Surgeons of Columbia University ^*  (United States)

ⁱ STANFORD UNIVERSITY   (United States)

^j STONY BROOK UNIVERSITY   (United States)

^k MASSACHUSETTS GENERAL HOSPITAL   (United States)

more..

Author keywords

Combining biomarkers; Differential treatment response index; Moderator; Optimizing treatment decisions; Precision medicine

Indexed keywords

ANTIDEPRESSANT AGENT;

ARTICLE; CLINICAL DECISION MAKING; CLINICAL FEATURE; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR DEPRESSION; PERSONALIZED MEDICINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SAMPLE SIZE; STATISTICAL ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 85014508995     PISSN: 24518654     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.conctc.2017.02.007     Document Type: Article

References (53)

1. [1] Abayomi, K., Gelman, A., Levy, M., Diagnostics for multiple imputations. Appl. Stat. 57 (2008), 273–291.
2. [2] Anderson, K., Odell, P., Wilson, P., Kannel, W., Cardiovascular disease risk profiles. Am. Heart J. 121 (1991), 293–298.
3. [3] Breiman, L., Friedman, J.H., Alshen, R.A., Stone, C.J., CART: Classification and Regression Trees. 1983, Wadsworth, Belmont, CA.
4. [4] Cattaneo, A., Gennerelli, M., Uher, R., Breen, G., Farmer, A., Aitchison, K., Craig, I., Anacker, C., Zunsztain, P., McGuffin, P., Pariante, C., Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline ‘predictors’ and longitudinal ‘targets’. Neuropsychopharmacology 38 (2013), 377–385.
5. [5] Chakraborty, B., Laber, E., Zhao, Y., Inference for optimal treatment regimes using adaptive m-Out-of-n bootstrap scheme. Biometrics 69 (2013), 714–723.
6. [6] Chen, W., Ghosh, D., Raghunatan, T., Norkin, M., Sargent, D., Bepler, G., On Bayesian methods of exploring qualitative interactions for targeted treatment. Stat. Med. 31 (2012), 3693–3707.
7. [7] Ciarleglio, A., Petkova, E., Tarpey, T., Ogden, R.T., Treatment decisions based on scalar and functional baseline covariates. Biometrics 71 (2015), 884–894.
8. [8] Ciarleglio, A., Petkova, E., Tarpey, T., Ogden, R.T., Flexible functional regression methods for estimating individualized treatment regimes. STAT 5 (2016), 185–199.
9. [9] Ciarleglio, A., Petkova, E., Tarpey, T., Ogden, R.T., Variable selection for treatment decision rules with scalar and functional predictors. Stat. Med. (In revision), 2017.
10. [10] Cloitre, M., Petkova, E., Su, Z., Weiss, B., Patient characteristics as a moderator of PTSD treatment outcome: combining symptom burden and strengths. Br. J. Psychiat. Open 2 (2016), 101–106.
11. [11] Cortes, C., Vapnik, V., Support-vector networks. Mach. Learn. 20 (1995), 273–297.
12. [12] Fan, J., Lv, J., Sure independence screening for ultra-high dimensional feature space. J. of the R. Stat. Soc. Ser. B 70 (2008), 849–911.
13. [13] Fava, M., Rush, A.J., Trivedi, M., Nierenberg, A.A., Thase, M.E., Sackheim, H.A., Quitkin, F.M., Wisniewski, S.R., Lavori, P.W., Rosenbaum, J.F., Kupfer, D.J., Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiat. Clinics of N. Am. 26 (2003), 457–494.
14. [14] Gunter, L., Zhu, J., Murphy, S., Variable selection for qualitative interactions in pres- onalized medicine while controlling the family-wise error rate. J. Biopharm. Stat. 21 (2011), 1063–1078.
15. [15] Hennings, J., Uhr, M., Klengel, T., Webber, P., Pütz, B., Czamara, D., Ising, M., Holsboer, F., Lucae, S., RNA expression profiling in depressed patients suggests retinoid-related orphan receptor alpha as a biomarker for antidepressant response. Translat. Psychiat., 5, 2015, e538.
16. [16] Korgaonkar, M., Williams, L., Song, Y., Usherwood, T., Grieve, S., Diffusion ten- sor imaging predictors of treatment outcomes in major depressive disorder. Br. J. Psychiat. 205 (2014), 321–328.
17. [17] Kraemer, H.C., Discovering, comparing, and combining moderators of treatment on outcome after randomized clinical trials: a parametric approach. Stat. Med. 32 (2013), 1964–1973.
18. [18] Krishnan, V., Nestler, E., The molecular neurobiology of depression. Nature 455 (2008), 894–902.
19. [19] Laber, E., Lizotte, D., Qian, M., Pelham, W., Murphy, S., Dynamic treatment regimes: technical challenges and applications. Electronic J. Stat. 8 (2014), 1225–1272.
20. [20] Laber, E., Zhao, Y.-Q., Tree-based methods for individualized treatment regimes. Biometrika 102 (2015), 501–514.
21. [21] Leuchter, A., Cook, I., Marangell, L., Gilmer, W., Burgoyne, K., Howland, R., Trivedi, M., Zisook, S., Jain, R., McCracken, T., Fava, M., Iosifescu, D., Greenwald, S., Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in major depressive disorder: results of the BRITE-MD study. Psychiat. Res. 169 (2009), 124–131.
22. [22] Li, J., Chan, I., Detecting qualitative interactions in clinical trials: an extension of range test. J. Biopharm. Stat. 16 (2006), 831–841.
23. [23] Liu, Y., Wang, Y., Kosorok, M., Zhao, Y.-Q., Zeng, D., Robust hybrid learning for estimating personalized dynamic treatment regimens. J. Am. Stat. Assoc. (Under Review), 2016.
24. [24] Lu, W., Zhang, H., Zeng, D., Variable selection for optimal treatment decision. Stat. Meth. Med. Res. 22 (2011), 493–504.
25. [25] McGrath, C., Kelley, M., Dunlop, B., Holtzheimer, P., Craighead, W., Mayberg, H., Pretreatment brain states identifying likely nonresponse to standard treatments for depression. Biol. Psychiat. 76 (2014), 527–535.
26. [26] Mundt, J., Vogel, A., Feltner, D., Lenderking, W., Vocal acoustic biomarkers of depres- sion severity and treatment response. Biol. Psychiat. 72 (2012), 580–587.
27. [27] Murphy, S., Optimal dynamic treatment regimes (with discussion). J. R. Stat. Soc. Ser. B 58 (2003), 331–366.
28. [28] Petkova, E., Tarpey, T., Partitioning of functional data for understanding heterogeneity in psychiatric conditions. Stat. Interface 2 (2009), 413–424.
29. [29] Petkova, E., Tarpey, T., Ciarleglio, A., Ogden, R.T., Deriving a scalar measure from a longitudinal trajectory with applications to placebo response. Stat. Med., 2016 (Submitted for publication).
30. [30] Petkova, E., Tarpey, T., Ogden, R., Su, Z., Generated effect modifiers (GEMs) in randomized clinical trials. Biostatistics 18:1 (2017), 105–118.
31. [31] Qian, M., Murphy, S., Performance guarantees for individualized treatment rules. Ann. Stat. 39 (2011), 1180–1210.
32. [32] Ramsay, J.O., Silverman, B.W., Functional Data Analysis. second ed., 2005, Springer, New York.
33. [33] Robins, J., Optimal structured nested models for optimal sequential decisions. Lin, D., Heagerty, P.J., (eds.) Proceedings of the Second Seattle Symposium on Biostatistics, 2004, Springer, New York, 189–326.
34. [34] Rubin, D., Estimating causal effects of treatments in randomized and nonrandomized studies. J. Edu. Psychol. 66 (1974), 688–701.
35. [35] Rush, A.J., Trivedi, M.H., Wisniewski, S.R., Nierenberg, A.A., Stewart, J.W., Warden, D., Niederehe, G., Thase, M.E., Lavory, P.W., Lebowitz, B.D., McGrath, P.J., Rosenbaum, J.F., Sackeim, H.A., Kupfer, D.J., Luther, J., Fava, M., Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiat. 163 (2006), 1905–1917.
36. [36] Schafer, J.L., Analysis of Incomplete Multivariate Data. 1997, Chapmen and Hall, New York.
37. [37] Schafer, J.L., Multiple imputation: a primer. Stat. Meth. Med. Res. 8 (1999), 3–15.
38. [38] Song, R., Kosorok, M., Zeng, D., Zhao, Y., Laber, E.B., Yuan, M., On sparse representation for optimal individualized treatment selection with penalized outcome weighted learning. STAT 4 (2015), 59–68.
39. [39] Song, X., Pepe, M., Evaluating markers for selecting a patient's treatment. Biometrics 60 (2004), 874–883.
40. [40] Su, Y.-S., Gelman, A., Hill, J., Yajima, M., Multiple imputation with diagnostics (mi) in R: opening windows into the black box. J. Stat. Softw. 45:1 (2011), 1–31.
41. [41] Tarpey, T., Petkova, E., Lu, Y., Govindarajulu, U., Optimal partitioning for linear mixed effects models: applications to identifying placebo responders. J. American Statistical Association 105 (2010), 968–977.
42. [42] Tarpey, T., Petkova, E., Ogden, R.T., Profiling placebo responders by self-consistent partitioning of functional data. J. Am. Stat. Assoc. 98 (2003), 850–858.
43. [43] Tarpey, T., Petkova, E., Zhu, L., A new approach to stratified psychiatry via convexity-based clustering with applications towards moderator analysis. Stat Interface 9 (2016), 255–266.
44. [44] Tian, L., Alizadeh, A., Gentles, A., Tibshirani, R., A simple method for estimating interactions between a treatment and a large number of covariates. J. Am. Stat. Assoc. 109 (2014), 1517–1532.
45. [45] Tibshirani, R., Regression shrinkage and selection via the LASSO. J. R. Stat. Soc. Ser. B 58 (1996), 267–288.
46. [46] Trivedi, M.H., McGrath, P., Fava, M., Parsey, R.V., Kurian, B., Phillips, M.L., Oquendo, M.A., Bruder, G., Pizzagalli, D., Toups, M., Cooper, C., Adams, P., Weyandt, S., Morris, D., Grannemann, B., Ogden, R.T., Buckner, R., McInnis, M., Kraemer, H.C., Petkova, E., Carmody, T., Weissman, M., Establishing Moderators and Biosignatures of Antidepressant Response in Clinical care (EMBARC): rationale and design. J. Psychiat. Res. 78 (2016), 11–23.
47. [47] Trivedi, M.H., Rush, A.J., Wisniewski, S.R., Nierenberg, A.A., Warden, D., Ritz, L., Norquist, G., Howland, R.H., Lebowitz, B., McGrath, P.J., Shores-Wilson, K., Biggs, M.M., Balasub- ramani, G.K., Fava, M., Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiat. 163 (2006), 28–40.
48. [48] Uher, R., Tansey, K., Dew, T., Maier, W., Mors, O., Hauser, J., Dernovsek, M., Heingsburg, N., Souery, D., A.F, McGuffin, P., An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. Am. J. Psychiat. 171 (2014), 1278–1286.
49. [49] Wang, R., Ware, J., Detecting moderator effects using subgroup analyses. Prev. Sci. 14 (2013), 111–120.
50. [50] Wellek, S., Testing for absence of qualitative interactions between risk factors and treatment effect. Biometric. J. 39 (1997), 809–821.
51. [51] Wolkowitz, O.M., Mellon, S.H., Epel, E.S., Lin, J., Reus, V.I., Dhabhar, F.S., Blackburn, E.H., Resting leukocyte telomerase activity is elevated in major depression and predicts treatment response. Mol. Psychiat. 17 (2012), 164–172.
52. [52] Zhang, B., Tsiatis, A.A., Davidian, M., Zhang, M., Laber, E., Estimating optimal treatment regimes from classification perspective. STAT 1 (2012), 103–114.
53. [53] Zhao, Y., Zeng, D., Rush, A.J., Kosorok, M.P., Estimating individualized treatment rules using outcome weighted learning. J. Am. Stat. Assoc. 107 (2012), 1106–1118.